Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

After univariate survival analysis using the Cox regression, biomarkers such as GDF-15, suPAR, calcidiol, and FGF23 were associated with readmissions.

Source: 2.3. Hospital Readmissions for Heart Failure. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

After hospital discharge, all patients were referred to the HFU of our hospital and included in the specific follow-up programme of this unit.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

New Biomarkers in the Prognostic Assessment of Acute Heart Failure with Reduced Ejection Fraction: Beyond Natriuretic Peptides

Study design awaiting verification · International Journal of Molecular Sciences · 2025

Original publication title

New Biomarkers in the Prognostic Assessment of Acute Heart Failure with Reduced Ejection Fraction: Beyond Natriuretic Peptides

Marcelino Cortés; Jairo Lumpuy-Castillo; Camila Sofía García-Talavera; María Belén Arroyo Rivera; Lara de Miguel; Antonio José Bollas; Jose Maria Romero-Otero; Jose Antonio Esteban Chapel; Mikel Taibo-Urquía; Ana María Pello; María Luisa González-Casaus; Ignacio Mahíllo-Fernández; Oscar Lorenzo; José Tuñón

© 2025 by the authors.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Natriuretic peptides are established biomarkers related to the prognosis of heart failure. New biomarkers have emerged in the field of cardiovascular disease. The prognostic value of these biomarkers in heart failure with reduced left ventricular ejection fraction is not well-established. We conducted a prospective, single-centre study, including (July 2019 to March 2023) 104 patients being consecutively admitted with a diagnosis of acute heart failure with reduced ejection fraction decompensation. The median follow-up was 23.5 months, during which 20 deaths (19.4%) and 21 readmissions for heart failure (20.2%) were recorded.

Plasma biomarkers, such as NT-proBNP, GDF-15, sST2, suPAR, and FGF-23, were associated with an increased risk of all-cause mortality. However, a Cox regression analysis showed that the strongest predictors of mortality were an estimated glomerular filtration rate (HR 0.96 [0.93 to 0.98]), GDF-15 (HR 1.3 [1.16 to 1.45]), and sST2 (HR 1.2 [1.11 to 1.35]). The strongest predictive model was formed by the combination of the glomerular filtration rate and sST2 (C-index 0.758). In conclusion, in patients with acute decompensated heart failure with reduced ejection fraction, GDF-15 and sST2 showed the highest predictive power for all-cause mortality, which was superior to other established biomarkers such as natriuretic peptides.

GDF-15 and sST2 may provide additional prognostic information to improve the prognostic assessment.

Authors’ abstract

Natriuretic peptides are established biomarkers related to the prognosis of heart failure. New biomarkers have emerged in the field of cardiovascular disease. The prognostic value of these biomarkers in heart failure with reduced left ventricular ejection fraction is not well-established. We conducted a prospective, single-centre study, including (July 2019 to March 2023) 104 patients being consecutively admitted with a diagnosis of acute heart failure with reduced ejection fraction decompensation. The median follow-up was 23.5 months, during which 20 deaths (19.4%) and 21 readmissions for heart failure (20.2%) were recorded.

Plasma biomarkers, such as NT-proBNP, GDF-15, sST2, suPAR, and FGF-23, were associated with an increased risk of all-cause mortality. However, a Cox regression analysis showed that the strongest predictors of mortality were an estimated glomerular filtration rate (HR 0.96 [0.93 to 0.98]), GDF-15 (HR 1.3 [1.16 to 1.45]), and sST2 (HR 1.2 [1.11 to 1.35]). The strongest predictive model was formed by the combination of the glomerular filtration rate and sST2 (C-index 0.758). In conclusion, in patients with acute decompensated heart failure with reduced ejection fraction, GDF-15 and sST2 showed the highest predictive power for all-cause mortality, which was superior to other established biomarkers such as natriuretic peptides.

GDF-15 and sST2 may provide additional prognostic information to improve the prognostic assessment.

Publication and source details

Original title: New Biomarkers in the Prognostic Assessment of Acute Heart Failure with Reduced Ejection Fraction: Beyond Natriuretic Peptides

Marcelino Cortés; Jairo Lumpuy-Castillo; Camila Sofía García-Talavera; María Belén Arroyo Rivera; Lara de Miguel; Antonio José Bollas; Jose Maria Romero-Otero; Jose Antonio Esteban Chapel; Mikel Taibo-Urquía; Ana María Pello; María Luisa González-Casaus; Ignacio Mahíllo-Fernández; Oscar Lorenzo; José Tuñón

International Journal of Molecular Sciences · 2025

* Correspondence: mcortesg@quironsalud.es© 2025 by the authors.2025https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).Carlos III Health Institute (ISCIII)PI20/00923PI24/00978Spain’s Ministry of Science and InnovationRTC2019-006826-1Spanish Society of CardiologyThis research was funded by grants from Carlos III Health Institute (ISCIII) (grant numbers PI20/00923; PI24/00978), Spain’s Ministry of Science and Innovation (grant number RTC2019-006826-1), and the Spanish Society of Cardiology.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T07:02:48.649231+00:00

DOI: 10.3390/ijms26030986 · PMC11817831